scholarly journals 2-deoxy-d-glucose therapy for preventing inflammatory cascade in COVID19 patients

2021 ◽  
Vol 15 (4) ◽  
pp. 467
Author(s):  
Abhijit Nair
Science ◽  
1994 ◽  
Vol 265 (5175) ◽  
pp. 1095-1098 ◽  
Author(s):  
D. Sylvestre ◽  
J. Ravetch

Author(s):  
Jeremiah Sundararaj Stanleyraj ◽  
Nandini Sethuraman ◽  
Rajesh Gupta ◽  
Sohanlal Thiruvoth ◽  
Manisha Gupta ◽  
...  

Abstract Severe COVID-19 is a biphasic illness, with an initial viral replication phase, followed by a cascade of inflammatory events. Progression to severe disease is predominantly a function of the inflammatory cascade, rather than viral replication per se. This understanding can be effectively translated to changing our approach in managing the disease. The natural course of disease offers us separate windows of specific time intervals to administer either antiviral or immunomodulatory therapy. Instituting the right attack at the right time would maximize the benefit of treatment. This concept must also be factored into studies that assess the efficacy of antivirals and immunomodulatory agents against COVID-19.


2005 ◽  
Vol 288 (2) ◽  
pp. F387-F398 ◽  
Author(s):  
Jianfeng Zheng ◽  
Kishor Devalaraja-Narashimha ◽  
Kurinji Singaravelu ◽  
Babu J. Padanilam

Increased generation of reactive oxygen species (ROS) and the subsequent DNA damage and excessive activation of poly(ADP-ribose) polymerase-1 (PARP-1) have been implicated in the pathogenesis of ischemic injury. We previously demonstrated that pharmacological inhibition of PARP protects against ischemic renal injury (IRI) in rats (Martin DR, Lewington AJ, Hammerman MR, and Padanilam BJ. Am J Physiol Regul Integr Comp Physiol 279: R1834–R1840, 2000). To further define the role of PARP-1 in IRI, we tested whether genetic ablation of PARP-1 attenuates tissue injury after renal ischemia. Twenty-four hours after reperfusion following 37 min of bilateral renal pedicle occlusion, the effects of the injury on renal functions in PARP−/− and PARP+/+ mice were assessed by determining glomerular filtration rate (GFR) and the plasma levels of creatinine. The levels of plasma creatinine were decreased and GFR was augmented in PARP−/− mice. Morphological evaluation of the kidney tissues showed that the extent of damage due to the injury in PARP−/− mice was less compared with their wild-type counterparts. The levels of ROS and DNA damage were comparable in the injured kidneys of PARP+/+ and PARP−/− mice. PARP activity was induced in ischemic kidneys of PARP+/+ mice at 6–24 h postinjury. At 6, 12, and 24 h after injury, ATP levels in the PARP+/+ mice kidney declined to 28, 26, and 43%, respectively, whereas it was preserved close to normal levels in PARP−/− mice. The inflammatory cascade was attenuated in PARP−/− mice as evidenced by decreased neutrophil infiltration and attenuated expression of inflammatory molecules such as TNF-α, IL-1β, and intercellular adhesion molecule-1. At 12 h postinjury, no apoptotic cell death was observed in PARP−/− mice kidneys. However, by 24 h postinjury, a comparable number of cells underwent apoptosis in both PARP−/− and PARP+/+ mice kidneys. Thus activation of PARP post-IRI contributes to cell death most likely by ATP depletion and augmentation of the inflammatory cascade in the mouse model. PARP ablation preserved ATP levels, renal functions, and attenuated inflammatory response in the setting of IRI in the mouse model. PARP inhibition may have clinical efficacy in preventing the progression of acute renal failure complications.


Author(s):  
Joshua T. Weinreb ◽  
Noura Ghazale ◽  
Kith Pradhan ◽  
Varun Gupta ◽  
Kathryn S. Potts ◽  
...  
Keyword(s):  

1996 ◽  
Vol 77 (1) ◽  
pp. 11-16 ◽  
Author(s):  
H F Galley ◽  
N R Webster
Keyword(s):  

1978 ◽  
Vol 276 (3) ◽  
pp. 305-310 ◽  
Author(s):  
LAWRENCE C. MAGUIRE ◽  
BARRY M. SHERMAN ◽  
JOHN E. WHALEN

2021 ◽  
Vol 22 (19) ◽  
pp. 10402
Author(s):  
Karina Wierzbowska-Drabik ◽  
Aleksandra Lesiak ◽  
Małgorzata Skibińska ◽  
Michał Niedźwiedź ◽  
Jarosław D. Kasprzak ◽  
...  

It is known that both psoriasis (PSO) limited to the skin and psoriatic arthritis (PSA) increase the risk of cardiovascular complications and atherosclerosis progression by inducing systemic inflammatory response. In recent decades, the introduction of biological medications directed initially against TNF-α and, later, different targets in the inflammatory cascade brought a significant breakthrough in the efficacy of PSO/PSA treatment. In this review, we present and discuss the most recent findings related to the interplay between the genetics and immunology mechanisms involved in PSO and PSA, atherosclerosis and the development of cardiac dysfunction, as well as the current PSO/PSA treatment in view of cardiovascular safety and prognosis.


Sign in / Sign up

Export Citation Format

Share Document